FT522 With Rituximab in Relapsed/​Refractory B-Cell Lymphoma (FT522-101)

General Information

Summary This is a phase 1 study of FT522 administered with rituximab in participants with relapsed/refractory B-cell lymphoma (R/R BCL). The primary objectives of the study are to evaluate the safety and tolerability of FT522 in combination with rituximab, and to determine the recommended phase 2 dose (RP2D) of FT522 in combination with rituximab; each objective will be assessed with or without conditioning chemotherapy.
Clinical trials phase Phase 1
Start date (estimated) 2023-09-01
End date (estimated) 2039-12-31
Clinical feature
Label B-cell lymphoma
Link http://purl.obolibrary.org/obo/DOID_707
Description A non-Hodgkin lymphoma that has_material_basis_in B cells.

Administrative Information

NCT number NCT05950334
ICTRP weblink https://trialsearch.who.int/Trial2.aspx?TrialID=NCT05950334
Other study identifiers
Name FT522-101
Source weblink https:/clinicaltrials.gov/ct2/show/NCT05950334
Regulatory body approval
Name Food and Drug Administration (FDA)
United States
Public contact
Email info@fatetherapeutics.com
Public email info@fatetherapeutics.com
Sponsors Fate Therapeutics


Which differentiated cell type is used
Label natural killer cell
Link http://purl.obolibrary.org/obo/CL_0000623
Description A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells.


Recruitment Status Not yet recruiting
Estimated number of participants 322